The manufacturers of Tamiflu Gilead Sciences,  has research and development facilities across North America, Europe, and Australia with a shared a vision of advancing therapeutics for life-threatening diseases worldwide. A leading biopharmaceutical company, Gilead is active in discovering, developing and commercialising small molecule therapeutics to advance the care of patients suffering from life-threatening infectious diseases.

Gilead, in addition to their marketed products, has a clinical, preclinical and research department focused on developing anti-infection drugs. The need to develop these types of drugs has always been in the forefront research and development pharmaceutical companies. Because of the recent development of new strains of influenzas such as the Bird Flu, the importance of developing drugs to combat these strains of influenza is now critical. Gilead takes great pride in their accomplishments in this area of the research and development of unique therapeutics. By disciplined science, visionary thinking and diversified planning Gilead has accomplished much in the fight against influenzas.

Gilead Sciences is a biopharmaceutical company that discovers, develops and markets innovative therapeutics in areas of previous unmet medical needs. They wish to advance the care of patients suffering from life-threatening diseases worldwide.

Formed in 1987 Gilead technology and product development programs have been constantly evolving and efficiently advancing the care of patients suffering from life-threatening infectious diseases. The development of Tamiflu highlights and have helped shape the company's scientific focus, its business strategy and its mission to discover, develop and market therapeutics which advance patient care. Gilead employs approximately 1900 employees and has operations in North America and in 10 countries throughout Europe and Australia.

The corporate headquarters are based in Foster City, California, with additional operations in San Dimas, California and Durham, North Carolina.  Its European operations are based in Cambridge, United Kingdom; Dublin, Ireland and Paris, France.

Gilead has established a network of exclusive distributors in more than 40 countries in Eastern Europe, Scandinavia, the Middle East, Asia, Africa and South America. This network supports a growing market share with collaborative efforts for obtaining new regulatory approvals. Development of new and stronger medicines to combat new strains of disease continues today.